Category Archives: Int’l Practice and Policy

NOVARTIS A.G. v. UOI – What is Novelty in Indian Courts?

Can everything old be made new again?  Lots has been written about the Indian Supreme Court rejecting a patent application claiming a crystal modification of imatinib mesylate (Gleevec), which is used to treat CML.  Novartis’ attempt to “evergreen” Gleevec with … Continue reading

Posted in Int'l Practice and Policy, Obviousness | Tagged , , , , | Leave a comment

Deposit of Biological Material – Impact on Validity of Priority Claim

Please find linked below a guest post from Dr. Stefan Danner dealing with a new decision of the EPO Technical Boards of Appeal concerning the deposit of biological material. Biotech IP Newsletter  

Posted in Int'l Practice and Policy | Tagged , , , , , | Leave a comment

“Global Dossier” May Lead to IP5 “One Portal” Filings

As reported in Director Kappos’ blog, progress is being made in harmonizing the patent filing process in the IP5 countries. This may be as big an advance in patent law as the EPO – including our hope for a single … Continue reading

Posted in Int'l Practice and Policy | Tagged , , , , , , | Leave a comment

Major Changes to IP Law in Australia Enacted

This guest post by Tom Gumley, PhD, a partner in the well-known Freehills Patent and Trademark firm provides a lengthy guide to the changes wrought by Australia’s new patent law, that was enacted on April 15, 2012. The law brings … Continue reading

Posted in Int'l Practice and Policy | Tagged , , , , , , , , | Leave a comment